z-logo
Premium
“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
Author(s) -
Conceição Isabel,
GonzálezDuarte Alejandra,
Obici Laura,
Schmidt Hartmut H.J.,
Simoneau Damien,
Ong MohLim,
Amass Leslie
Publication year - 2016
Publication title -
journal of the peripheral nervous system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 67
eISSN - 1529-8027
pISSN - 1085-9489
DOI - 10.1111/jns.12153
Subject(s) - transthyretin , medicine , carpal tunnel syndrome , amyloidosis , polyneuropathy , amyloid (mycology) , pathology , surgery
Transthyretin familial amyloid polyneuropathy ( TTR‐FAP ) is a rare, progressive, life‐threatening, hereditary disorder caused by mutations in the transthyretin gene and characterized by extracellular deposition of transthyretin‐derived amyloid fibrils in peripheral and autonomic nerves, heart, and other organs. TTR‐FAP is frequently diagnosed late because the disease is difficult to recognize due to phenotypic heterogeneity. Based on published literature and expert opinion, symptom clusters suggesting TTR‐FAP are reviewed, and practical guidance to facilitate earlier diagnosis is provided. TTR‐FAP should be suspected if progressive peripheral sensory‐motor neuropathy is observed in combination with one or more of the following: family history of a neuropathy, autonomic dysfunction, cardiac hypertrophy, gastrointestinal problems, inexplicable weight loss, carpal tunnel syndrome, renal impairment, or ocular involvement. If TTR‐FAP is suspected, transthyretin genotyping, confirmation of amyloid in tissue biopsy, large‐ and small‐fiber assessment by nerve conduction studies and autonomic system evaluations, and cardiac testing should be performed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here